Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures

NCT ID: NCT02140528

Last Updated: 2017-04-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a case-control prospective, clinal trial to assess the safety and efficacy of the allogeneic adipose derived mesenchymal stem cell transplantation on the healing of recent tibial fracture in 40 patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study all eligible patients divided in 2 group.20 patients received allogeneic adipose derived mesenchymal stem cell in the fractured site (case group) and other patients received the placebo in the fractured site (control group) .

To assess the outcomes, we will evaluate the patients at 2, 6 weeks and 3, 6 months after transplantation by: X-ray, BMD , VAS and biochemical analysis with laboratory tests.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tibial Fracture

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mesenchymal stem cell receipients

Transplantation of allogenic adipose derived mesenchymal stem cells in patients with tibial fracture.

Group Type EXPERIMENTAL

Mesenchymal stem cell injection

Intervention Type BIOLOGICAL

Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .

Placebo

Placebo injection in the site of fracture in patients with tibia fracture.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mesenchymal stem cell injection

Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .

Intervention Type BIOLOGICAL

Placebo

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

stem cell transplantation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 to 65 years
* The presence of tibial fracture based on X ray
* tibial fracture is limited to diaphysial

Exclusion Criteria

* Addiction
* Pregnancy
* liver or kidney disease or uncontrolled diabetes or heart and lung disease
* immune deficiency
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Royan Institute

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hamid Gourabi, PhD

Role: STUDY_CHAIR

Head of Royan Institute

Nasser Aghdami, MD,PhD

Role: STUDY_DIRECTOR

Head of regenerative medicine department &cell therapy center of Royan Institute

Mohsen Emaddedin, MD

Role: STUDY_DIRECTOR

Department or regenerative medicine of Royan Institute.

Aziz Ahmadi, MD

Role: PRINCIPAL_INVESTIGATOR

Scientific board of Iranian Orthopedic Association

Maedeh Ghorbani, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Regenerative Medicine

Afshin Farhadi, MD

Role: PRINCIPAL_INVESTIGATOR

Scientific board of Iranian Orthopedic Association

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royan Institute

Tehran, , Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Royan-Bone-012

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.